1. In Vivo

Hang Onto The Launch: Investor Outlook Is Brighter For Some Biotechs

Successful biotech launches like Regeneron’s Eylea, Vertex’s Incivek and others have investors reconsidering the “short the launch” mentality that pervaded the industry a year ago, though no one is throwing caution to the wind.

One year ago, after being burned by disappointing sales of drugs like Dendreon Corp.’s Provenge and Human Genome Sciences Inc.’s Benlysta, investors swore off biotechs in the midst of a commercial launch. The savvy strategy was to make money selling biotech stocks at the inflection point of drug approval rather than betting on a drug’s longer-term commercial potential, and “short the launch” became the mantra of the day.

But over the last 12 months, biotech has been cranking out new drugs, and a few have gotten off to...

More from Archive

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.